We also demonstrated the potential efficacy of combining p53 activators with elesclomol-Cu to significantly suppress tumor growth, thereby providing a novel therapeutic strategy with potential clinical applications in the treatment of HCC. The gene discussed is TP53; the disease is hepatocellular carcinoma.